UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, exercised 9,500 stock options and sold the resulting 9,500 United Therapeutics (UTHR) common shares for approximately $5.1 million via a family trust under a 10b5-1 plan.

On July 20, 2026, United Therapeutics Corporation Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at an exercise price of $135.42 per share into common stock held indirectly by a family trust, and on the same day the trust sold the 9,500 resulting common shares in a series of nine open-market transactions at weighted average prices between approximately $529.19 and $536.41 per share, for total sale proceeds of about $5.06 million. The option exercise itself was a non-cash transaction (Form 4 shows $0.00 for the derivative transaction price) and added 9,500 shares to the trust's indirect common stock holdings before they were sold. Following these transactions, the reporting person’s direct ownership stands at 40,513 common shares, with additional indirect holdings including 166 shares held by spouse and several blocks of shares held through multiple family trusts (249,108; 45,596; and 8,902 shares) as well as stock options held in a family trust. The exercise-and-sale activity was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is intended to systematically exercise up to 1,734,410 options expiring March 15, 2027, or until December 31, 2026, thereby characterizing the transactions as part of a scheduled diversification and liquidity program rather than a discretionary insider trade.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000102

Alert Tier

7